BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. More Details
Adequate balance sheet with limited growth.
Share Price & News
How has BIOLASE's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BIOL is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 29% a week.
Volatility Over Time: BIOL's weekly volatility has decreased from 39% to 29% over the past year, but is still higher than 75% of US stocks.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: BIOL underperformed the US Medical Equipment industry which returned 20% over the past year.
Return vs Market: BIOL underperformed the US Market which returned 19.6% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is BIOLASE's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StHealth Check: How Prudently Does BIOLASE (NASDAQ:BIOL) Use Debt?
6 months ago | Simply Wall StNews Flash: 3 Analysts Think BIOLASE, Inc. (NASDAQ:BIOL) Earnings Are Under Threat
7 months ago | Simply Wall StWhat Does The Future Hold For BIOLASE, Inc. (NASDAQ:BIOL)? These Analysts Have Been Cutting Their Estimates
Is BIOLASE undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BIOL's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate BIOL's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: BIOL is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: BIOL is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BIOL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BIOL is overvalued based on its PB Ratio (5.7x) compared to the US Medical Equipment industry average (5.1x).
How is BIOLASE forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BIOL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BIOL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BIOL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BIOL's revenue (37.1% per year) is forecast to grow faster than the US market (10.2% per year).
High Growth Revenue: BIOL's revenue (37.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BIOL's Return on Equity is forecast to be high in 3 years time
How has BIOLASE performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BIOL is currently unprofitable.
Growing Profit Margin: BIOL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BIOL is unprofitable, and losses have increased over the past 5 years at a rate of 4.1% per year.
Accelerating Growth: Unable to compare BIOL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BIOL is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.3%).
Return on Equity
High ROE: BIOL has a negative Return on Equity (-103.05%), as it is currently unprofitable.
How is BIOLASE's financial position?
Financial Position Analysis
Short Term Liabilities: BIOL's short term assets ($36.0M) exceed its short term liabilities ($21.4M).
Long Term Liabilities: BIOL's short term assets ($36.0M) exceed its long term liabilities ($6.7M).
Debt to Equity History and Analysis
Debt Level: BIOL's debt to equity ratio (116.1%) is considered high.
Reducing Debt: BIOL's debt to equity ratio has increased from 0% to 116.1% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BIOL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BIOL has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 5.1% each year.
What is BIOLASE current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BIOL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BIOL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BIOL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BIOL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BIOL's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Todd Norbe (53 yo)
Mr. Todd A. Norbe is President and Chief Executive Officer at BIOLASE, Inc. since August 7, 2018. He served as President of Dental/Medical Solutions at Sybron Dental Specialties, Inc. Mr. Norbe serves as t...
CEO Compensation Analysis
Compensation vs Market: Todd's total compensation ($USD592.59K) is about average for companies of similar size in the US market ($USD533.86K).
Compensation vs Earnings: Todd's compensation has been consistent with company performance over the past year.
|Executive VP||3.25yrs||US$446.56k||0.39% |
|National Sales Director||no data||US$243.55k||no data|
|Vice President of Human Resources||4.67yrs||no data||no data|
|Chief Dental Officer and VP of Dental & Clinical Affairs||4.25yrs||US$50.44k||no data|
|VP & MD of Europe||4.33yrs||no data||no data|
|Corporate Secretary||no data||no data||no data|
|Vice President of Finance and Corporate Controller||6yrs||no data||no data|
|Director of Education & Events||no data||no data||no data|
Experienced Management: BIOL's management team is considered experienced (4.3 years average tenure).
|Independent Director||3.25yrs||US$116.50k||0.16% |
|Independent Chairman of the Board||3.33yrs||US$249.60k||0.55% |
|Independent Director||1.17yrs||US$6.52k||no data|
|Independent Director||2.58yrs||US$104.17k||0.17% |
|Independent Director||2.75yrs||US$116.50k||0.18% |
|Independent Director||2.25yrs||US$116.50k||0.12% |
Experienced Board: BIOL's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 202.2%.
BIOLASE, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: BIOLASE, Inc.
- Ticker: BIOL
- Exchange: NasdaqCM
- Founded: 1984
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$77.894m
- Shares outstanding: 93.51m
- Website: https://www.biolase.com
Number of Employees
- BIOLASE, Inc.
- 4 Cromwell
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BIOL||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Mar 1992|
|BTH1||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Mar 1992|
BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental lase...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/17 00:56|
|End of Day Share Price||2021/01/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.